⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087164 | 1.00 | — | — | |
| SCHEMBL10087163 | 1.00 | — | — | |
| SCHEMBL478333 | 0.85 | ALDH1A1 (0.31) | — | |
| SCHEMBL17793262 | 0.82 | — | — | |
| SCHEMBL3981059 | 0.79 | — | — | |
| SCHEMBL16247738 | 0.76 | — | — | |
| SCHEMBL6176028 | 0.73 | — | — | |
| SCHEMBL17133775 | 0.73 | — | — | |
| SCHEMBL7952674 | 0.73 | — | — | |
| SCHEMBL17789897 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170052449-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND | OSAKA UNIVERSITY (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3133444-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND | OSAKA UNIVERSITY (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9563121-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, and, actinic ray-sensitive or radiation-sensitive film and pattern forming method, each using the composition | FUJIFILM CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-20150086912-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM AND PATTERN FORMING METHOD USING THE SAME, MANUFACTURING METHOD OF SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2015-03-26 | — | — | US | disclosed |
| US-20140342275-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, AND, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM AND PATTERN FORMING METHOD, EACH USING THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |